Reducing Cardiogenic Shock Mortality by Improving the Coronary Microcirculation

A portable system enabling catheter anchoring and long-term dose response.

30–50%
In-hospital mortality
Cardiogenic Shock (CS)
>$40K
Median cost per CS
hospitalization (US)
~100K
CS cases per year
in the US and Europe
52%
Catheter displacement rate,
existing technology

The Problem

Cardiogenic shock kills 1 in 3 patients, even with best-in-class mechanical circulatory support.

Unreliable anchoring of previous therapies led to inconsistent occlusion.

Our Solution

Clinical Proof of Concept: CorVena Therapy — Coronary Venous Pressure Modulation (CVPM)

The proprietary CorVena Therapy delivers controlled coronary venous pressure pulses to support the ischemic myocardium.

Proof of Concept: Complete LV Function Recovery

Recovery attributed to a higher dose and longer duration of coronary sinus pulsation.

Before
After
15 days on IABP and Impella with no LV function recovery prior to high-dose coronary sinus pulsation.
Complete LV function recovery confirmed on echo within 12 hours of coronary sinus pulsation
Case courtesy Dr. Azeem Latib
Montefiore Health System, New York

Team

Co-Founder & Clinical Lead
Dr. Azeem Latib
Co-Founder & CEO
Jon H. Hoem
Co-Founder & Preclinical Lead
Nikola Cesarovic, PhD

Join us in eliminating preventable cardiogenic shock deaths.

hello@resurgentheart.com
Resurgent Heart AG (under incorporation), Baar (ZG), Switzerland